TIGIT in cancer immunotherapy von Chauvin, Joe-Marc, Zarour, Hassane M

Volltext

Emerging Opportunities and Challenges in Cancer Immunotherapy von Whiteside, Theresa L, Demaria, Sandra, Rodriguez-Ruiz, Maria E, Zarour, Hassane M, Melero, Ignacio

Volltext

Reversing T-cell Dysfunction and Exhaustion in Cancer von Zarour, Hassane M

Volltext

In memoriam: Soldano Ferrone, MD, PhD (1940–2023) von Whiteside, Theresa, Zarour, Hassane M

Volltext

Tim-3 mediates T cell trogocytosis to limit antitumor immunity von Pagliano, Ornella, Morrison, Robert M, Chauvin, Joe-Marc, Banerjee, Hridesh, Davar, Diwakar, Ding, Quanquan, Tanegashima, Tokiyoshi, Gao, Wentao, Chakka, Saranya R, DeBlasio, Richelle, Lowin, Ava, Kara, Kevin, Ka, Mignane, Zidi, Bochra, Amin, Rada, Raphael, Itay, Zhang, Shuowen, Watkins, Simon C, Sander, Cindy, Kirkwood, John M, Bosenberg, Marcus, Anderson, Ana C, Kuchroo, Vijay K, Kane, Lawrence P, Korman, Alan J, Rajpal, Arvind, West, Sean M, Han, Minhua, Bee, Christine, Deng, Xiaodi, Schebye, Xiao Min, Strop, Pavel, Zarour, Hassane M

Volltext

Microbiome-derived metabolites counteract tumor-induced immunosuppression and boost immune checkpoint blockade von Zarour, Hassane M

Volltext

Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy von Davar, Diwakar, Zarour, Hassane M

Volltext

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis von Bastacky, Melissa L, Wang, Hong, Fortman, Dylan, Rahman, Zahra, Mascara, Gerard P, Brenner, Timothy, Najjar, Yana G, Luke, Jason J, Kirkwood, John M, Zarour, Hassane M, Davar, Diwakar

Volltext

IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell von Shao, Lulu, Hou, Weizhou, Scharping, Nicole E, Vendetti, Frank P, Srivastava, Rashmi, Roy, Chandra Nath, Menk, Ashley V, Wang, Yiyang, Chauvin, Joe-Marc, Karukonda, Pooja, Thorne, Stephen H, Hornung, Veit, Zarour, Hassane M, Bakkenist, Christopher J, Delgoffe, Greg M, Sarkar, Saumendra N

Volltext

Next Generation of Immunotherapy for Melanoma von KIRKWOOD, John M, TARHINI, Ahmad A, PANELLI, Monica C, MOSCHOS, Stergios J, ZAROUR, Hassane M, BUTTERFIELD, Lisa H, GOGAS, Helen J

Volltext

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 von Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., Wolchok, J.D., Hersey, P., Joseph, R., Weber, J.S., Dronca, R., Mitchell, T.C., Patnaik, A., Zarour, H.M., Joshua, A.M., Zhao, Q., Jensen, E., Ahsan, S., Ibrahim, N., Ribas, A.

Volltext

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma von Shaikh, Saba S, Zang, Yan, Hanmer, Janel, Wang, Hong, Lin, Yan, Davar, Diwakar, Zarour, Hassane M, Kirkwood, John M, Najjar, Yana G

Volltext

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients von Chauvin, Joe-Marc, Pagliano, Ornella, Fourcade, Julien, Sun, Zhaojun, Wang, Hong, Sander, Cindy, Kirkwood, John M, Chen, Tseng-hui Timothy, Maurer, Mark, Korman, Alan J, Zarour, Hassane M

Volltext

Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment von Bender, Mackenzie J., McPherson, Alex C., Phelps, Catherine M., Pandey, Surya P., Laughlin, Colin R., Shapira, Jake H., Medina Sanchez, Luzmariel, Rana, Mohit, Richie, Tanner G., Mims, Tahliyah S., Gocher-Demske, Angela M., Cervantes-Barragan, Luisa, Mullett, Steven J., Gelhaus, Stacy L., Bruno, Tullia C., Cannon, Nikki, McCulloch, John A., Vignali, Dario A.A., Hinterleitner, Reinhard, Joglekar, Alok V., Pierre, Joseph F., Lee, Sonny T.M., Davar, Diwakar, Zarour, Hassane M., Meisel, Marlies

Volltext

Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors von Davar, Diwakar, Zarour, Hassane M.

Volltext

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients von Fourcade, Julien, Sun, Zhaojun, Benallaoua, Mourad, Guillaume, Philippe, Luescher, Immanuel F, Sander, Cindy, Kirkwood, John M, Kuchroo, Vijay, Zarour, Hassane M

Volltext

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells von Sun, Zhaojun, Fourcade, Julien, Pagliano, Ornella, Chauvin, Joe-Marc, Sander, Cindy, Kirkwood, John M, Zarour, Hassane M

Volltext

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 von McCulloch, John A., Davar, Diwakar, Rodrigues, Richard R., Badger, Jonathan H., Fang, Jennifer R., Cole, Alicia M., Balaji, Ascharya K., Vetizou, Marie, Prescott, Stephanie M., Fernandes, Miriam R., Costa, Raquel G. F., Yuan, Wuxing, Salcedo, Rosalba, Bahadiroglu, Erol, Roy, Soumen, DeBlasio, Richelle N., Morrison, Robert M., Chauvin, Joe-Marc, Ding, Quanquan, Zidi, Bochra, Lowin, Ava, Chakka, Saranya, Gao, Wentao, Pagliano, Ornella, Ernst, Scarlett J., Rose, Amy, Newman, Nolan K., Morgun, Andrey, Zarour, Hassane M., Trinchieri, Giorgio, Dzutsev, Amiran K.

Volltext

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy) von Ascierto, Paolo A, Puzanov, Igor, Agarwala, Sanjiv S, Blank, Christian, Carvajal, Richard D, Demaria, Sandra, Dummer, Reinhard, Ernstoff, Marc, Ferrone, Soldano, Fox, Bernard A, Gajewski, Thomas F, Garbe, Claus, Hwu, Patrick, Lo, Roger S, Long, Georgina V, Luke, Jason J, Osman, Iman, Postow, Michael A, Sullivan, Ryan J, Taube, Janis M, Trinchieri, Giorgio, Zarour, Hassane M, Caracò, Corrado, Thurin, Magdalena

Volltext

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma von Slingluff, Craig L., Zarour, Hassane M., Tawbi, Hussein Abdul-Hassan, Kirkwood, John M., Postow, Michael A., Friedlander, Philip, Devoe, Craig E., Gaughan, Elizabeth M., Mauldin, Ileana S., Olson, Walter C., Smith, Kelly T., Macri, Mary J., Ricciardi, Toni, Ryan, Aileen, Venhaus, Ralph, Wolchok, Jedd D.

Volltext